Product image of Irbesartan + Hidroclorotiazida Ciclum (Hydrochlorothiazide, Irbesartan) supplied by GNH India

Irbesartan + Hidroclorotiazida Ciclum

Active Ingredient:
Hydrochlorothiazide, Irbesartan
Origin:
EU

Irbesartan + Hidroclorotiazida Ciclum (Hydrochlorothiazide, Irbesartan)

Irbesartan, the active ingredient in Irbesartan + Hidroclorotiazida Ciclum, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension.

GNH India supplies Irbesartan + Hidroclorotiazida Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards, provides batch‑to‑batch consistency, and offers reliable logistics for global distribution. Customers benefit from responsive technical support and regulatory assistance throughout the procurement process.

Manufacturer / TM Owner

Ciclum Farma Unipessoal Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin system and renal sodium handling to control high blood pressure.

  • Hypertension: reduces systolic and diastolic pressure in patients with essential hypertension.
  • Hypertension with edema: assists in fluid‑overload management while lowering blood pressure.
  • Hypertension in type 2 diabetes: provides blood pressure control with added renal protective benefits.

How It Works

  • Irbesartan selectively blocks the AT1 receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, promoting diuresis, reducing plasma volume, and enhancing the antihypertensive effect of irbesartan.

Side Effects

The combination may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Dizziness
  • Headache
  • Fatigue
  • Increased urination
  • Electrolyte disturbances (e.g., low potassium or sodium)
  • Mild gastrointestinal upset

Serious or Rare Side Effects

  • Severe dehydration
  • Hyperkalemia
  • Acute kidney injury
  • Angioedema
  • Severe hypotension
  • Allergic skin reactions

Precautions & Warnings

When prescribing Irbesartan/Hydrochlorothiazide, clinicians should observe several safety considerations.

  • Monitor blood pressure: ensure target levels are achieved without excessive drop.
  • Assess renal function: check serum creatinine and eGFR before and during therapy.
  • Evaluate electrolytes: watch for potassium and sodium abnormalities.
  • Use caution in elderly: increased sensitivity to blood‑pressure changes.
  • Avoid in severe hepatic impairment: limited safety data.
  • Store at room temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Irbesartan/Hydrochlorothiazide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Aliskiren: combined use may increase risk of renal impairment and hyperkalemia.
  • Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
  • Lithium: increased lithium levels and toxicity risk.
  • ACE inhibitors or other ARBs: additive effects on blood pressure and potassium.
  • High‑dose NSAIDs: may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

  • Other antihypertensives: may cause additive hypotension, dose adjustment needed.
  • CYP2C9 inhibitors (e.g., fluconazole): can increase irbesartan plasma levels.
  • Antidiabetic drugs: diuretic‑induced changes in glucose may require dose modification.
  • Regular‑dose NSAIDs: monitor renal function and electrolytes.
  • Antacids containing aluminum/magnesium: may affect absorption of hydrochlorothiazide.

Frequently Asked Questions

Irbesartan + Hidroclorotiazida Ciclum is a fixed‑dose combination of an angiotensin II receptor blocker and a thiazide diuretic. It is prescribed to lower elevated blood pressure in adults with hypertension, often when a single agent does not achieve target control.

Irbesartan blocks the AT1 receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release. This leads to relaxation of blood vessels and reduced fluid retention, contributing to lower blood pressure.

The specific dose is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any concomitant medications. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety in pregnancy and lactation has not been established for this combination. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapy, the Irbesartan/Hydrochlorothiazide combination offers complementary mechanisms—vascular relaxation and diuresis—allowing more effective blood‑pressure reduction at lower individual doses, which can improve tolerability relative to higher‑dose monotherapy.

Store the tablets at room temperature, below 25 °C, in the original container. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

Serious adverse events can include severe dehydration, hyperkalemia, acute kidney injury, angioedema and marked hypotension. Patients should be monitored for signs of these conditions, especially when initiating therapy or adjusting doses.

The combination should be avoided in individuals with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation, as well as in patients with severe hepatic impairment or those taking contraindicated medications such as aliskiren in diabetic patients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Hydrochlorothiazide, Irbesartan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT